Northwestern Cancer Prevention Consortium

西北癌症预防联盟

• 批准号: 10686120
• 负责人: SEEMA Ahsan KHAN
• 金额: $ 193.54万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-03 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10686120
• 关键词: Advisory Committees; Area; Biological; Biological Markers; Breast; Cancer Center Support Grant; Cancer Prevention Trial; Cancer Science; Cities; Clinic; Clinical; Clinical Research; Clinical Trials; Collaborations; Colon; Colon Carcinoma; Communication; Comprehensive Cancer Center; Conduct Clinical Trials; Consultations; Development; Disease; Dose; Drug Delivery Systems; Ensure; Evaluation; Fostering; Fright; Genetic Predisposition to Disease; Goals; Incidence; Individual; Institution; Intervention; Investigation; Knowledge; Leadership; Lesion; Liver; Lung; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Mentors; Methods; Monitor; Mutation; New Agents; Organ; Pancreas; Pathology; Pathway interactions; Patients; Pharmaceutical Preparations; Physicians; Population; Prevention; Prevention Research; Process; Reproducibility; Research; Research Infrastructure; Research Personnel; Resources; Science; Scientist; Site; Sum; Technology; Testing; Toxic effect; Transdermal substance administration; Universities; Work; biomarker selection; cancer chemoprevention; cancer prevention; cancer therapy; cancer type; design; drug repurposing; early phase clinical trial; early phase trial; improved; innovation; malignant breast neoplasm; malignant oropharynx neoplasm; member; nanoarchitecture; novel; novel marker; predictive marker; programs; protocol development; recruit; reduce symptoms; success; targeted agent; trial design

Northwestern University proposes to continue to lead a consortium of organizations, the Northwestern Cancer Prevention Consortium (NCPC), to design and conduct early phase clinical trials aimed at developing new options for the prevention of cancer. To date, NCPC trials, 19 in total, have accrued 534 patients (354 from the 2003 consortium and 175 from the 2012 consortium), targeting multiple organ sites and a variety of agents. We have tested innovative concepts, e.g., transdermal drug delivery, and utilized novel biomarkers, such as nanocytological alterations. Our proposal to renew the NCPC, under the leadership of Seema A. Khan MD includes academic partners included in the current consortium and new members who are expected to add important strengths to it (the University of Toronto and City of Hope). In the new cycle of the NCPC, we will continue to build on promising approaches based on prior or ongoing successful trials, while providing oversight, consultation, and administrative support to cancer prevention research teams. We will assist in the design of cancer prevention trials, in proposal and protocol development, and in the implementation of such trials. Our overarching goal is to continue our contributions to cancer prevention science through the development of innovative, transformative, early phase trials testing new conceptual approaches that will enable clinical advances in the prevention of cancer. Our Aims are to 1. Advance high priorities in cancer prevention, for maximum impact on cancer incidence when these are advanced into clinical use. These priorities include (i) investigate novel agents and repurposed agents that target mutations and pathways known to be important in the development of cancer, (ii) novel or established biomarkers to identify individuals most like to predict benefit from a given approach, (iii) trials that will result in unifying biological themes across different organ sites, leading to protection against more than one cancer type, (iv) test innovative dosing and delivery methods, to reduce the symptom and toxicity burden for users of cancer prevention agents. 2. Provide consultation, scientific guidance, and mentoring to consortium investigators who are proposing new trial concepts; assist consortium investigators through trial design, initiation, conduct, and analysis; and to serve as the administrative hub of the consortium. We will foster communication, collaboration, and sharing of available resources between consortium members and across consortia, to maximize impact of clinical trials testing similar interventions or in similar populations. Serve as a liaison between the consortium and the NCI DCP, by maintaining and improving an NCPC 3. Advance the science of cancer prevention, through evaluation and selection of innovative or transformative concepts that result in progress that is greater than the sum of knowledge gained from the specific goals of an individual trial. We will be guided in this process by an Advisory Committee with a diverse background in cancer prevention research.

西北大学建议继续领导一个组织联盟，即西北癌症 预防财团（NCPC），设计和进行旨在开发新的临床试验 预防癌症的选择。迄今为止，NCPC试验总共有534名患者（354例 2003年财团，2012年财团中有175个财团，针对多个器官和各种代理。我们 已经测试了创新概念，例如透皮药物输送并利用了新型生物标志物，例如 纳米细胞学改变。我们在Seema A. Khan MD的领导下续签NCPC的建议 包括当前财团中包括的学术合作伙伴和期望添加的新成员 它的重要优势（多伦多大学和希望之城）。在NCPC的新周期中，我们将 继续基于以前或正在进行的成功试验的有希望的方法，同时提供 对癌症预防研究团队的监督，咨询和行政支持。我们将协助 设计预防癌症试验，提案和协议开发以及实施 试验。我们的总体目标是继续我们对癌症预防科学的贡献 通过开发创新，变革性的早期试验测试新概念 可以在预防癌症方面取得临床进展的方法。我们的目标是1。 提高预防癌症的高度优先级，以最大程度地影响癌症发生率 前进到临床用途。这些优先级包括（i）调查新型代理和重新利用的代理 靶突变和已知在癌症发展中很重要的途径，（ii）新颖或 建立的生物标志物以确定最喜欢从给定方法中预测利益的个人（iii）试验 这将导致跨不同器官站点统一生物主题，从而防止更多 比一种癌症类型（IV）测试创新的给药和递送方法，以减轻症状和 对预防癌症用户的毒性负担。 2。提供咨询，科学指导和 向提议新审判概念的联盟调查员进行指导；协助财团调查员 通过试验设计，启动，行为和分析；并充当行政枢纽 财团。我们将促进沟通，协作和共享可用资源 在财团成员和整个财团之间，以最大程度地提高临床试验测试的影响 干预措施或类似人群。作为财团和NCI DCP之间的联络 维持和改善NCPC 3。通过评估提高预防癌症的科学 以及导致进步大于总和的创新或变革概念的选择 从个人试验的具体目标中获得的知识。我们将在此过程中受到指导 由具有癌症预防研究背景不同的咨询委员会。